Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Immune targeting of the microenvironment in classical Hodgkin lymphoma

Catherine Diefenbach • 19 Jun 2019
ICML 2019
Hodgkin Lymphoma Lymphoma AFM13 Brentuximab vedotin Checkpoint inhibitors Ipilimumab Nivolumab
E4412

Catherine Diefenbach, MD, NYU Langone, New York, NY, discusses the immune targeting of the microenvironment in classical Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Catherine Diefenbach

6:45
Brentuximab vedotin with nivolumab ± ipilimumab in R/R HL: outcomes with and without autoSCT
Catherine Diefenbach • 11 Dec 2023
1:34
How will bispecifics impact the treatment of NHL?
Catherine Diefenbach • 11 Dec 2022
2:31
Long-term follow up of study of obinutuzumab, polatuzumab vedotin, and lenalidomide in R/R FL
Catherine Diefenbach • 11 Dec 2022
1:30
Advances in the management of R/R Hodgkin lymphoma
Catherine Diefenbach • 11 Dec 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals